(Q47288494)

English

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus (English)

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

type 2 diabetes

0 references

author name string

Yochai Birnbaum

1

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Alexander C Castillo

2

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Jinqiao Qian

3

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Shukuan Ling

4

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Hongmei Ye

5

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Jose R Perez-Polo

6

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Mandeep Bajaj

7

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Yumei Ye

8

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

publication date

1 December 2012

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Cardiovascular Drugs and Therapy

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

26

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

6

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

445-456

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cardiovascular effects of the DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cardioprotective effects of incretin during ischaemia-reperfusion

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Mechanisms of action of glucagon-like peptide 1 in the pancreas

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol as a Unique Antithrombotic Agent

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Preconditioning the diabetic heart: the importance of Akt phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumor necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in SK-N-SH cells

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endotheli

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

cAMP-PKA signaling to the mitochondria: protein scaffolds, mRNA and phosphatases

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Structural basis for activation and inhibition of class I phosphoinositide 3-kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cardiac regulation by phosphoinositide 3-kinases and PTEN

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Phosphorylation keeps PTEN phosphatase closed for business

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Survival kinases in ischemic preconditioning and postconditioning.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

CREB activation and ischaemic preconditioning

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Cilostazol: therapeutic potential against focal cerebral ischemic damage

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

CREB is a novel nuclear target of PTEN phosphatase

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Resolvin E1 protects the rat heart against reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS10557-012-6409-X

21 January 2018

Identifiers

10.1007/S10557-012-6409-X

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

1 reference

Europe PubMed Central

13 January 2018

http://europepmc.org/abstract/MED/22936458

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47288494&oldid=2150541221"